

## Drug Interactions with Methadone

Antiretroviral	Effect on Methadone	Effect on Antiretroviral	Potential Significance / Recommendation
<b>Nucleoside Reverse Transcriptase Inhibitors</b>			
zidovudine (AZT)	None	<b>May</b> ↑ AZT levels	No dose adjustments; Watch for signs/symptoms of AZT adverse effects (e.g. headache, muscle aches, fatigue, irritability).
didanosine EC (ddl)	None	No interactions with EC formulation	No dose adjustments with enteric-coated capsule.
zalcitabine (ddC)	Unknown	Unknown	Unknown
stavudine (d4T)	None	<b>May</b> ↓ d4T levels	No dose adjustments; Monitor CD4 and viral load to ensure d4T efficacy.
lamivudine (3TC)	None	Unknown	Unknown
emtricitabine (FTC)	Unknown	Unknown	Unknown
abacavir (ABC)	<b>May</b> ↑ methadone clearance; ↓ levels	<b>May</b> delay the time it takes abacavir to be absorbed.	Monitor for signs/symptoms of withdrawal.
<b>Nucleotide Reverse Transcriptase Inhibitors</b>			
tenofovir (TDF)	None	None	Combination appears safe.

Antiretroviral	Effect on Methadone	Effect on Antiretroviral	Potential Significance / Recommendation
<b>Protease Inhibitors</b>			
indinavir (IDV)	None	<b>May</b> ↑ IDV Cmin; ↓ Cmax	Combination appears safe.
atazanavir (ATV)	Unknown	Unknown	Unknown
ritonavir (RTV)	<b>May</b> ↓ methadone levels (variable)	Unknown	<b>May</b> need increased methadone dose.
nelfinavir (NFV)	<b>May</b> ↓ methadone levels (variable)	None	Monitor for signs/symptoms of withdrawal; adjust dose if necessary.
saquinavir (FTV;INV)	Unknown	Unknown	Unknown
fosamprenavir (fAPV)	Minor decrease in R-methadone	Unknown	No evidence of opioid withdrawal
lopinavir/ritonavir (LPV/r)	<b>May</b> ↓ methadone levels (variable)	Unknown	Monitor for signs/symptoms of withdrawal; adjust dose if necessary. Results variable.
SQV/RTV Combination	<b>May</b> ↓ S-methadone and R-methadone levels	Unknown	No evidence of opioid withdrawal; adjust dose if necessary.

Antiretroviral	Effect on Methadone	Effect on Antiretroviral	Potential Significance / Recommendation
<b>Non-nucleoside Reverse Transcriptase Inhibitors</b>			
nevirapine (NVP)	<b>May</b> ↓ methadone levels	Unknown	<b>May</b> need increased methadone dose; Monitor for signs/symptoms of withdrawal.
delavirdine (DLV)	<b>May</b> ↑ methadone levels (predicted)	None	<b>May</b> need decreased methadone dose; watch for signs of opioid toxicity.
efavirenz (EFV)	<b>May</b> ↓ methadone levels	Unknown	<b>May</b> need increased methadone dose; Monitor for signs/symptoms of withdrawal.

References:

Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: A review. Mt Sinai J Med. 2000; 67:429-36.

Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry M, Back DJ. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis. 2002;34:1143-5.

Hendrix CW, Wakeford J, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy. 2004 Sep;24(9):1110-21.

Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002 Oct;36(10):1598-613.

Smith PF, Kearney BP, Liaw S, Cloen D, Bullock JM, Haas CE, Yale K, Booker BM, Berenson CS, Coakley DF, Flaherty JF. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Pharmacotherapy. 2004 Aug;24(8):970-7.